Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus

For the Diabetes Control, Complications Trial (DCCT)/Epidemiology of Diabetes Interventions, Complications (EDIC) Study

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We examined if urinary angiotensinogen (uAOG), a marker of intrarenal renin-angiotensin system activity, antedates stage 3 chronic kidney disease (CKD) using samples from participants in the Diabetes Control and Complications Trial (DCCT) and later in the Epidemiology of Diabetes Intervention and Complications (EDIC) trial. In a nested case–control design, cases were matched at the outcome visit (eGFR less than 60, 21-59 mL/min per 1.73 m2) on age, gender, and diabetes duration, with controls: eGFR (95, 75-119, mL/min per 1.73 m2.) Additionally, in an exploratory analysis progressive renal decline (PRD), defined as eGFR loss >3.5 mL/min per 1.73m2/year, was evaluated using only data from EDIC because no progressions were observed during DCCT. At the EDIC visit, which antedated the GFR outcome visit by 2 years (range 1–7years) the median uAOG/creatinine was markedly higher in cases than in controls (13.9 vs. 3.8 ng/mg P = 0.003) whereas at the DCCT visit, which antedated the GFR outcome by 17 to 20 years it was not (2.75 vs. 3.16 ng/mg, respectively). The Odds Ratio for uAOG and CKD stage 3 development was significant after adjusting for eGFR, HbA1c, and systolic blood pressure 1.82 (1.00–3.29) but no longer significant when Albumin Excretion Ratio (AER) was included 1.21 (0.65–2.24).In the PRD analysis, uAOG/creatinine was sixfold higher in participants who experienced PRD than in those who did not (26 vs. 4.0 ng/mg, P = 0.003). The Odds Ratio for uAOG and PRD was significant after adjusting for eGFR, HbA1c, and systolic blood pressure 2.48 (1.46–4.22) but no longer significant when AER was included 1.32 (0.76–2.30). In people with type1 diabetes, a robust increase in uAOG antedates the development of stage 3 CKD but is not superior to AER in predicting this renal outcome. Increased uAOG moreover is associated with PRD, an index of progression to End Stage Kidney Disease (ESKD).

Original languageEnglish (US)
Article numbere14242
JournalPhysiological reports
Volume7
Issue number19
DOIs
StatePublished - Oct 1 2019

Keywords

  • biomarkers
  • chronic kidney disease
  • diabetes
  • hypertension
  • renin angiotensin system
  • urinary angiotensinogen

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus'. Together they form a unique fingerprint.

Cite this